Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation

Journal of Inflammation Research

Volumn 3, Issue 1, 2010, Pages 143-170

  Das, Undurti N ^a,b  

^a JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^b UND LIFE SCIENCES   (United States)

Author keywords

Free radicals; Lipoxins; Lupus; Polyunsaturated fatty acids; Resolvins; Rheumatology

Indexed keywords

ACETYLSALICYLIC ACID; AUTOANTIBODY; BELIMUMAB; C REACTIVE PROTEIN; CALCITRIOL; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; ESSENTIAL FATTY ACID; GHRELIN; GLUCOCORTICOID; HIGH MOBILITY GROUP B1 PROTEIN; INSULIN; LIPOXYGENASE; MACROPHAGE MIGRATION INHIBITION FACTOR; METHOTREXATE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PYRUVIC ACID DERIVATIVE; PYRUVIC ACID ETHYL ESTER; RECOMBINANT GAMMA INTERFERON; RITUXIMAB; SERUM AMYLOID P; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CARDIOVASCULAR RISK; CD4+ CD25+ T LYMPHOCYTE; CELL INFILTRATION; CHEMICAL STRUCTURE; CHOLINERGIC STIMULATION; CHROMATIN; CHRONIC INFLAMMATION; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; DRUG MEGADOSE; ECZEMA; EFFECTOR CELL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FATTY ACID METABOLISM; GENE EXPRESSION; GLOMERULONEPHRITIS; GLOMERULUS; GRAFT REJECTION; GRAFT SURVIVAL; HORMONE ACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; INTERFERON PRODUCTION; KERATINOCYTE; LEUKEMIA; LEUKOCYTE FUNCTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MACROPHAGE; MAST CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN DEPHOSPHORYLATION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL; ULTRAVIOLET RADIATION; UVEITIS; VAGUS NERVE STIMULATION; VAGUS TONE; VASODILATATION; VITILIGO;

EID: 78650615776     PISSN: None     EISSN: 11787031     Source Type: Book Series    
DOI: 10.2147/JIR.S9425     Document Type: Article

References (209)

1. Das UN. Clinical laboratory tools to diagnose inflammation. Adv Clin Chem. 2006;41:189-229.
2. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids. 2005;73(3-4):141-162.
3. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A. 1995;92(21):9475-9479.
4. Das UN. COX-2 inhibitors and metabolism of essential fatty acids. Med Sci Monit. 2005;11(7):RA233-RA237.
5. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196:1025-1037.
6. Das UN. Can COX-2 inhibitors-induced increase in cardiovascular disease risk be modifed by essential fatty acids? J Assoc Physicians India. 2005;53:623-627.
7. Chiang N, Arita M, Serhan CN. Anti-infammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids. 2005;73:163-177.
8. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2(7):612-619.
9. Serhan CN, Maddox JF, Petasis NA, et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry. 1995;34(44):14609-14615.
10. Kerr DJ, Dunn JA, Langman MJ, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med. 2007;357(4):360-369.
11. Xiao G, Tasi A-L, Palmer G, Boyar WC, Marshall PJ, Kulmacz RJ. Analysis of hydroperoxide-induced tyrosyl radicals and lipoxyge-nase activity in aspirin-treated human prostaglandin H synthase-2. Biochemistry. 1997;36(7):1836-1845.
12. Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther. 2010;125(3):446-463.
13. Nithipatikom K, Gross GJ. Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection. J Cardiovasc Pharmacol Ther. 2010;15(2):112-119.
14. Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endothelium-dependent responses. Pfugers Arch. 2010;459(6):881-895.
15. Arnold C, Konkel A, Fischer R, Schunck WH. Cytochrome P450- dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol Rep. 2010;62(3): 536-547.
16. Kroetz DL, Zeldin DC. Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol. 2002;13(3):273-283.
17. Gao L, Yin H, Milne GL, Porter NA, Morrow JD. Formation of F-ring isoprostane-like compounds (F3-isoprostanes) in vivo from eicosap-entaenoic acid. J Biol Chem. 2006;281(20):14092-14099.
18. Grimminger F, Mayser P, Papavassilis C, et al. A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis. Rapid improvement of clinical manifestations and changes in neutrophil leukotriene profile. Clin Investig. 1993;71(8):634-643.
19. Serhan CN, Clish CB, Brannon J, Colgan S P, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflamma-tory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000;192(8):1197-1204.
20. Serhan CN, Clish CB, Brannon J, Colgan S P, Gronert K, Chiang N. Anti-microinfammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. J Physiol Pharmacol. 2000;51(4 Pt 1):643-654.
21. Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem. 2003;278(44): 43807-43817.
22. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-infammation. J Biol Chem. 2003;278(17):14677-14687.
23. Katoh T, Lakkis FG, Makita N, Badr KF. Co-regulated expression of glomerular 12/15-lipoxygenase and interleukin-4 mRNAs in rat nephrotoxic nephritis. Kidney Int. 1994;46(2):341-349.
24. Nassar GM, Badr KF. Role of leukotrienes and lipoxygenases in glom-erular injury. Miner Electrolyte Metab. 1995;21(4-5):262-270.
25. Papayianni A, Serhan CN, Phillips ML, Rennke HG, Brady HR. Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int. 1995;47(5):1295-1302.
26. O'Meara YM, Brady HR. Lipoxins, leukocyte recruitment and the resolution phase of acute glomerulonephritis. Kidney Int Suppl. 1997;58:S56-S61.
27. Wu SH, Liao PY, Yin PL, Zhang YM, Dong L. Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. Am J Pathol. 2009;174(1):115-122.
28. Lattin JE, Schroder K, Su AI, et al. Expression analysis of G protein-coupled receptors in mouse macrophages. Immunome Res. 2008;4:5.
29. Milligan G, Stoddart LA, Brown AJ. G protein-coupled receptors for free fatty acids. Cell Signal. 2006;18(9):1360-1365.
30. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):687-698.
31. Baugh JA, Donnelly SC. Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J Endocrinol. 2003;179(1):15-23.
32. Das UN. Can critical illness and sepsis be predicted or prognosticated? Adv Sepsis. 2006;5:52-59.
33. Gando S, Sawamura A, Hayakawa M, Hoshino H, Kubota N, Nishihira J. High macrophage migration inhibitory factor levels in disseminated intravascular coagulation patients with systemic inflammation. Infammation. 2007;30(3-4):118-124.
34. Chuang CC, Wang ST, Chen WC, Chen CC, Hor LI, Chuang AY. Increases in serum macrophage migration inhibitory factor in patients with severe sepsis predict early mortality. Shock. 2007;27(5):503-506.
35. Hoi AY, Hickey MJ, Hall P, et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulo-nephritis, and lethality in MRL/lpr mice. J Immunol. 2006;177(8): 5687-5696.
36. Mizue Y, Nishihira J, Miyazaki T, et al. Quantitation of macrophage migration inhibitory factor (MIF) using the one-step sandwich enzyme immunosorbent assay: elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes. Int J Mol Med. 2000;5(4):397-403.
37. Das UN. Insulin in the critically ill with focus on cytokines, reactive oxygen species, HLA-DR expression. J Assoc Physicians India. 2007; 55 Suppl:56-65.
38. Bozza FA, Gomes RN, Japiassú AM, et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock. 2004;22(4):309-313.
39. Das UN. Current advances in sepsis and septic shock with particular emphasis on the role of insulin. Med Sci Monit. 2003;9(8):RA181-RA192.
40. Lehmann LE, Novender U, Schroeder S, et al. Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med. 2001;27(8):1412-1415.
41. Bozza M, Satoskar AR, Lin G, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med. 1999;189(2):341-346.
42. Rovensky J, Svejcar J, Pekarek J, Zitnan D, Hajzok O, Cebecauer L. Correlation between the results of the migration inhibitory factor production test with DNA and the severity of the disease in the systemic lupus erythematosus patients. Z Immunitatsforsch Exp Klin Immunol. 1975;150(1):24-30.
43. Chen WY, Li GR, Fang F, et al. The expression of migration inhibitory factor in peripheral blood mononuclear cell and its correlation with disease activity in systemic lupus erythematosus. Zhonghua Nei Ke Za Zhi. 2004;43(8):572-575.
44. Ayoub S, Hickey MJ, Morand EF. Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nature Clin Pract Rheumatol. 2008;4:98-105.
45. Otukesh H, Chalian M, Hoseini R, et al. Urine macrophage migration inhibitory factor in pediatric systemic lupus erythematosus. Clin Rheumatol. 2007;26(12):2105-2107.
46. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol. 2004;31(2):268-273.
47. Urbonaviciute V, Fürnrohr BG, Meister S, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 2008;205(13):3007-3018.
48. Yin K, Gribbin E, Wang H. Interferon-gamma inhibition attenuates lethality after cecal ligation and puncture in rats: implication of high mobility group box-1. Shock. 2005;24(4):396-401.
49. Ayer LM, Rubin RL, Dixon GH, Fritzler MJ. Antibodies to HMG proteins in patients with drug-induced autoimmunity. Arthritis Rheum. 1994;37(1):98-103.
50. Popovic K, Ek M, Espinosa A, et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum. 2005;52(11):3639-3645.
51. Barkauskaite V, Ek M, Popovic K, Harris HE, Wahren-Herlenius M, Nyberg F. Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus. 2007;16(10):794-802.
52. Das UN. Interaction(s) between essential fatty acids, eicosanoids, cytokines, growth factors and free radicals: relevance to new therapeutic strategies in rheumatoid arthritis and other collagen vascular diseases. Prostaglandins Leukot Essent Fatty Acids. 1991;44(4):201-210.
53. Robak E, Sysa-Jeorzejewska A, Dziankowska B, Torzecka D, Chojnowski K, Robak T. Association of interferon gamma, tumor necrosis factor alpha and interleukin-6 serum levels with systemic lupus erythematosus activity. Arch Immunol Ther Exp (Warsz). 1998;46(6): 375-380.
54. Tucci M, Calvani N, Richards HB, Quatraro CQ, Silvestris F. The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. Ann N Y Acad Sci. 2005;1051:421-432.
55. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specifcity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988;318(25):1651-1657.
56. Shen JY, Chen SL, Wu YX, et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int. 1999;18(4):147-151.
57. Willeke P, Schluter B, Schotte H, et al. Increased frequency of GM-CSF secreting PBMC in patients with active systemic lupus erythematosus can be reduced by immunoadsorption. Lupus. 2004;13(4):257-262.
58. Williams RC Jr, Harmon ME, Burlingame R, Du Clos T W. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol. 2005;32(3):454-461.
59. Lindsey NJ, Henderson FI, Malia R, Milford-Ward MA, Greaves M, Hughes P. Inhibition of prostacyclin release by endothelial binding anti-cardiolipin antibodies in thrombosis-prone patients with systemic lupus erythematosus and the antiphospholipid syndrome. Br J Rheumatol. 1994;33(1):20-26.
60. Das UN. Benefcial action(s) of eicosapentaenoic acid/docosahexaenoic acid and nitric oxide in systemic lupus erythematosus. Med Sci Res. 1995;23:723-726.
61. Mohan IK, Das UN. Oxidant stress, anti-oxidants and essential fatty acids in systemic lupus erythematosus. Prostaglandins Leukot Essent Fatty Acids. 1997;56(3):193-198.
62. Zamora MR, O'Brien RF, Rutherford RF, Weil J V. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet. 1990;336(8724):1144-1147.
63. Reimann J, Diamantstein T. Interleukin-2 allows in vivo induction of anti-erythrocyte autoantibody production in nude mice associated with the injection of rat erythrocytes. Clin Exp Immunol. 1981;43(3):641-644.
64. Redini F, Galera P, Mauviel A, Loyau G, Pujol J-P. Transforming growth factor-beta stimulates collagen and glycosaminoglycan biosynthesis in cultured rabbit articular chondrocytes. FEBS Lett. 1988;234(1):172-176.
65. Falanga V, Julien JM. Observations in the potential role of transforming growth factor-beta in cutaneous fibrosis. Systematic sclerosis. Ann N Y Acad Sci. 1990;593:161-171.
66. Wong CK, Ho CY, Li EK, Lam C W. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus. 2000;9(8):589-593.
67. Horwitz DA, Gray JD, Behrendsen SC, et al. Decreased production of interleukin-12 and other Th1 type cytokines in patients with recent onset systemic lupus erythematosus. Arthritis Rheum. 1998;41(5): 838-844.
68. Takahashi S, Fossati L, Iwamoto M, et al. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J Clin Invest. 1996;97(7): 1597-1604.
69. Peng SL, Szabo SJ, Glimcher LH. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci U S A. 2002;99(8):5545-5550.
70. Akahoshi M, Nakashima H, Tanaka Y, et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum. 1999;42(8):1644-1648.
71. Chan RW, Tam LS, Li EK, et al. Infammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 2003;48(5):1326-1331.
72. Lighvani AA, Frucht DM, Jankovic D, et al. T-bet is rapidly induced by interferon gamma in lymphoid and myeloid cells. Proc Natl Acad Sci U S A. 2001;98(26):15137-15142.
73. Lantelme E, Mantovani S, Palermo B, Campanelli R, Sallusto F, Giachino C. Kinetics of GATA-3 gene expression in early polarizing and committed human T cells. Immunology. 2001;102(2): 123-130.
74. Lee HJ, Takemoto N, Kurata H, et al. GATA-3 induces T helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells. J Exp Med. 2000;192(1):105-115.
75. Arbuckle MR, McClain MT, Rubertone M V, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526-1533.
76. Thompson C, Powrie F. Regulatory T cells. Curr Opin Pharmacol. 2004;4(4):408-414.
77. Kammer GM, Perl A, Richardson BC, Tsokos GC. Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum. 2002;46(5):1139-1154.
78. Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest. 2004;114(9):1198-1208.
79. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172(7):3983-3988.
80. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4(9):665-674.
81. Lee JH, Wang LC, Lin YT, Yang YH, Lin DT, Chiang BL. Inverse correlation between CD4+ regulatory T-cell population and autoanti-body levels in paediatric patients with systemic lupus erythematosus. Immunolog y. 2006;117(2):280-286.
82. Valencia X, Yarboro C, Illei G, Lipsky PE. Defcient CD4+CD25high T regulatory cell function in patients with active systemic lupus ery-thematosus. J Immunol. 2007;178(4):2579-2588.
83. Lyssuk E Y, Torgashina AV, Soloviev SK, Nassaonov EL, Bykovskaia SN. Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol. 2007;601:113-119.
84. Lin SC, Chen KH, Lin CH, Kuo CC, Ling QD, Chan CH. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest. 2007;37(12):987-996.
85. Gaipl US, Sheriff A, Franz S, et al. Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol. 2006;305:161-176.
86. Kruse K, Janko C, Urbonaviciute V, et al. Ineffcient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis. 2010;15(9):1098-1113.
87. Kawai M, Kitade H, Mathieu C, Waer M, Pirenne J. Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation. 2005;79(9):1073-1077.
88. Schwarz T. 25 years of UV-induced immunosuppression mediated by T cells-from disregarded T suppressor cells to highly respected regulatory T cells. Photochem Photobiol. 2008;84(1):10-18.
89. Hart PH, Townley SL, Grimbaldeston MA, Khalil Z, Finlay-Jones JJ. Mast cells, neuropeptides, histamine, and prostaglandins in U V-induced systemic immunosuppression. Methods. 2002;28(1): 79-89.
90. Zhang Y, Ramos BF, Jakschik BA. Augmentation of reverse arthus reaction by mast cells in mice. J Clin Invest. 1991;88(3):841-846.
91. Danilewicz M, Wagrowska-Danilewicz M. Quantitative analysis of interstitial mast cells in lupus and non-lupus membranous glomerul-opathy. Pol J Pathol. 2001;52(4):211-217.
92. Eklund KK. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev. 2007;217:38-52.
93. Woolley DE, Tetlow LC. Mast cell activation and its relation to proin-fammatory cytokine production in the rheumatoid lesion. Arthritis Res. 2000;2(1):65-74.
94. Pablos JL, Santiago B, Galindo M, Carreira PE, Ballestin C, Gomez-Reino JJ. Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis. J Pathol. 1999;188(1):63-68.
95. Reefman E, de Jong MC, Kuiper H, et al. Is disturbed clearance of apoptotic keratinocytes responsible for UVB-induced infammatory skin lesions in systemic lupus erythematosus? Arthritis Res Ther. 2006;8(6):R156.
96. Ohira T, Arita M, Omori K, Recchiuti A, van Dyke TE, Serhan CN. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem. 2010;285(5):3451-3461.
97. Bonventre J V. Phospholipase A2 and signal transduction. J Am Soc Nephrol. 1992;3(2):128-150.
98. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol. 2000;164(4):1663-1667.
99. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-infammatory properties. Nat Med. 1999;5(6):698-701.
100. Gilroy DW, Newson J, Sawmynaden P, Willoughby DA, Croxtall JD. A novel role for phospholipase A2 isoforms in the checkpoint control of acute infammation. FASEB J. 2004;18(3):489-498.
101. Cominelli F, Nast CC, Llerena R, Dinarello CA, Zipser RD. Interleukin 1 suppresses infammation in rabbit colitis. Mediation by endogenous prostaglandins. J Clin Invest. 1990;85(2):582-586.
102. Schwab JH, Anderle SK, Brown RR, Dalldorf FG, Thompson RC. Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats. Infect Immun. 1991;59(12):4436-4442.
103. Croxtall JD, Choudhury Q, Tokumoto H, Flower RJ. Lipocortin-1 and the control of arachidonic acid release in cell signalling. Gluco-corticoids inhibit G protein-dependent activation of cPLA2 activity. Biochem Pharmacol. 1995;50(4):465-474.
104. Munck A, Guyre PM, Holbrook NJ. Physiological functions of glu-cocorticoids in stress and their relation to pharmacological actions. Endocr Rev. 1984;5(1):25-44.
105. Walev I, Klein J, Husmann M, et al. Potassium regulates IL-1 beta processing via calcium-independent phospholipase A2. J Immunol. 2000;164(10):5120-5124.
106. Wu C-C, Croxtall JD, Perretti M, et al. Lipocortin 1 mediates the inhibition by dexamethasone of the induction by endotoxin of nitric oxide synthase in the rat. Proc Natl Acad Sci U S A. 1995;92(8):3473-3477.
107. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR. Dex-amethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol. 2002;22(22):7802-7811.
108. Crafford LJ, Wilder RL, Ristimaki A P, et al. Cyclooxygenase-1 and -2 expression in rheumatoid arthritis synovial tissues. J Clin Invest. 1994;93(3):1095-1101.
109. Radomski M W, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A. 1990;87(24):10043-10047.
110. Hoeck WG, Ramesha CS, Chang DJ, Fan N, Heller RA. Cytoplasmic phospholipase A2 activity and gene expression are stimulated by tumor necrosis factor: dexamethasone blocks the inducible synthesis. Proc Natl Acad Sci U S A. 1993;90(10):4475-4479.
111. Kunicka JE, Talle MA, Denhardt GH, Brown M, Prince LA, Goldstein G. Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone. Cell Immunol. 1993;149(1):39-49.
112. Calandra T, Bernhagen J, Metz CN, et al. MIF as a gluco-corticoid-induced modulator of cytokine production. Nature. 1995;377(6544):68-71.
113. Salvemini D, Seibert K, Masferrer JL, Misko T P, Currie MG, Needleman P. Endogenous nitric oxide enhances prostaglan-din production in a model of renal infammation. J Clin Invest. 1994;93(5):1940-1947.
114. Zaitsu M, Hamasaki Y, Tsuji K, et al. Dexamethasone accelerates catabolism of leukotriene C4 in bronchial epithelial cells. Eur Respir J. 2003;22(1):35-42.
115. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral predni-sone on airway infammatory mediators in atopic asthma. Am J Respir Crit Care Med. 1994;149(4 Pt 1):953-959.
116. Ferrante J V, Ferrante A. Novel role of lipoxygenases in the infamma-tory response: promotion of TNF mRNA decay by 15-hydroperoxy-eicosatetraenoic acid in a monocytic cell line. J Immunol. 2005;174(6):3169-3172.
117. Ariel A, Chiang N, Arita M, Petasis NA, Serhan CN. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol. 2003;170(12):6266-6272.
118. Wu SH, Lu C, Dong L, Zhou GP, He ZG, Chen ZQ. Lipoxin A4 inhibits TNF-alpha-induced production of interleukins and proliferation of rat mesangial cells. Kidney Int. 2005;68(1):35-46.
119. Hayakawa M, Ishida N, Takeuchi K, et al. Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor. J Biol Chem. 1993;268(15):11290-11295.
120. Das UN. A Perinatal Strategy for Preventing Adult Disease: The Role of Long-chain Polyunsaturated Fatty Acids. Boston: Kluwer Academic Press; 2002.
121. Huang YS, Drummond R, Horrobin D F. Protective effect of gamma-linolenic acid on aspirin induced gastric hemorrhage in rats. Digestion. 1987;36(1):36-41.
122. Manjari V, Das UN. Effect of polyunsaturated fatty acids on dexamethasone-induced gastric mucosal damage. Prostaglandins Leukot Essent Fatty Acids. 2000;62(2):85-96.
123. Das UN. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-infammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis. 2008;7:37.
124. Das UN. Can essential fatty acids reduce the burden of disease(s)? Lipids Health Dis. 2008;7:9.
125. Das UN. Essential fatty acids - a review. Curr Pharm Biotechnol. 2006;7(6):467-482.
126. Krishna Mohan I, Das UN. Prevention of chemically induced diabetes mellitus in experimental animals by polyunsaturated fatty acids. Nutrition. 2001;17(2):126-151.
127. Suresh Y, Das UN. Long-chain polyunsaturated fatty acids and chemically-induced diabetes mellitus: effect of ω-6 fatty acids. Nutrition. 2003;19(2):93-114.
128. Suresh Y, Das UN. Long-chain polyunsaturated fatty acids and chemically-induced diabetes mellitus: effect of ω-3 fatty acids. Nutrition. 2003;19(3):213-228.
129. Suresh Y, Das UN. Differential effect of saturated, monounsatu-rated, and polyunsaturated fatty acids on alloxan-induced diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids. 2006;74(3): 199-213.
130. Das UN, Mohan IK, Raju TR. Effect of corticosteroids and eicosa-pentaenoic acid/docosahexaenoic acid on pro-oxidant and anti-oxidant status and metabolism of essential fatty acids in patients with glomerular disorders. Prostaglandins Leukot Essent Fatty Acids. 2001;65(4):197-203.
131. Das UN. Essential fatty acids: biochemistry, physiology, and pathology. Biotechnol J. 2006;1(4):420-439.
132. Kambe T, Murakami M, Kudo I. Polyunsaturated fatty acids potentiate interleukin-1-stimulated arachidonic acid release by cells overexpressing type IIA secretory phospholipase A2. FEBS Lett. 1999;453(1-2):81-84.
133. Das UN. Can perinatal supplementation of long-chain polyunsaturated fatty acids prevent atopy, bronchial asthma and other infammatory conditions? Med Sci Monit. 2006;12(6):RA99-RA111.
134. Belmont HM, Levartovsky D, Goel A, et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40(10):1810-1816.
135. Wanchu A, Khullar M, Deodhar SD, Bambery P, Sud A. Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Rheumatol Int. 1998;18(2):41-43.
136. Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. Proc Assoc Am Physicians. 1999;111(6):611-621.
137. Svenungsson E, Andersson M, Brundin L, et al. Increased levels of proinfammatory cytokines and nitric oxide metabolites in neu-ropsychiatric lupus erythematosus. Ann Rheum Dis. 2001;60(4): 372-379.
138. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol. 1999;26(2):318-324.
139. Yu CC, Yang C W, Wu MS, et al. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J Lab Clin Med. 2001;138(1):69-77.
140. Reilly CM, Oates JC, Sudian J, Crosby MB, Halushka P V, Gilkeson GS. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin Immunol. 2001;98(3):337-345.
141. Lemire JM, Adams JS, Kermani-Arab V, Bakke AC, Sakai R, Jordan SC. 1,25-Dihydroxyvitamin D3 suppresses human T helper/ inducer lymphocyte activity in vitro. J Immunol. 1985;134(5): 3032-3035.
142. Pichler J, Gerstmayr M, Szépfalusi Z, Urbanek R, Peterlik M, Willheim M. 1 alpha,25(OH)2D3 inhibits not only Th1 but also Th2 differentiation in human cord blood T cells. Pediatr Res. 2002;52(1): 12-18.
143. Tang J, Zhou R, Luger D, et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol. 2009;182(8):4624-4632.
144. Huang LW, Chang KL, Chen CJ, Liu H W. Arginase levels are increased in patients with rheumatoid arthritis. Kaohsiung J Med Sci. 2001;17(7):358-363.
145. Bultink IE, Teerlink T, Heijst JA, Dijkmans BA, Voskuyl AE. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64(9):1362-1365.
146. Svenungsson E, Cederholm A, Jensen-Urstad K, Fei GZ, de Faire U, Frostegård J. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythema-tosus. Scand J Rheumatol. 2008;37(5):352-359.
147. Gustafsson J, Gunnarsson I, Börjesson O, et al. Predictors of the frst cardiovascular event in patients with systemic lupus erythe-matosus - a prospective cohort study. Arthritis Res Ther. 2009; 11(6):R186.
148. Das UN. Benefcial effect of L-arginine in collagen vascular diseases: a role for nitric oxide. Nutrition. 1993;9(3):277-278.
149. Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafl in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112(19):2980-2985.
150. Yoshizumi M, Kunihara H, Morita T, et al. Interleukin-1 increases the production of endothelin-1 by cultured endothelial cells. Biochem Biophys Res Commun. 1990;166(1):324-329.
151. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber S. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66(4):807-815.
152. Dong G, Panaro F, Bogetti D, et al. Standard chronic immuno-suppression after kidney transplantation for systemic lupus ery-thematosus eliminates recurrence of disease. Clin Transplant. 2005;19(1):56-60.
153. Tanaka H, Oki E, Tsuruga K, Yashiro T, Hanada I, Ito E. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose. Clin Nephrol. 2009;72(6):430-436.
154. Yoon KH. Effcacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review. J Biomed Biotechnol. 2010;2010:686480.
155. Pego-Reigosa JM, Isenberg DA. Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. Expert Opin Investig Drugs. 2008;17(1):31-41.
156. Edwards JC, Szczepanski L, Szechinski J, et al. Effcacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581.
157. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs. 2006;66(15):1933-1948.
158. Ding C, Foote S, Jones G. B-cell-targeted therapy for systemic lupus erythematosus: an update. BioDrugs. 2008;22(4):239-249.
159. Hicks PS, Saunero-Nava L, Du Clos T W, Mold C. Serum amyloid P component binds to histones and activates the classical complement pathway. J Immunol. 1992;149(11):3689-3694.
160. Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med. 1999;5(6):694-697.
161. Gillmore JD, Hutchinson WL, Herbert J, et al. Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP defciency or strain combination? Immunology. 2004;112:255-264.
162. Braun A, Sis J, Max R, et al. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol. 2007;36(4):291-298.
163. Soma M, Tamaoki T, Kawano H, et al. Mice lacking serum amyloid P component do not necessarily develop severe autoimmune disease. Biochem Biophys Res Commun. 2001;286(1):200-205.
164. Tsukamoto H, Horiuchi T. Clinical aspects of the complement system. Rinsho Byori. 2006;54(7):757-762.
165. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34(3):J276-J286.
166. Braude IA, Hochberg MC, Arnett FC, Waldmann TA. In vitro suppression of anti-DNA antibody and immunoglobulin synthesis in systemic lupus erythematosus patients by human gamma interferon. J Rheumatol. 1988;15(3):438-444.
167. Nicoletti F, Meroni P, di Marco R, et al. In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse. Immuno pharmacolog y. 1992;24(1):11-16.
168. Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus. 2008;17(5):394-399.
169. Satomi N, Sakurai A, Haranaka K. Relationship of hypoglyce-mia to tumor necrosis factor production and antitumor activity: role of glucose, insulin, and macrophages. J Natl Cancer Inst. 1985;74(6):1255-1260.
170. Fraker DL, Merino MJ, Norton JA. Reversal of the toxic effects of cachectin by concurrent insulin administration. Am J Physiol. 1989;256(6 Pt 1):E725-E731.
171. Ottlecz A, Koltai M, Blazso G, Minker E. Contribution to the regulatory role of insulin in infammation and anaphylaxis. Int Arch Allergy Appl Immunol. 1978;56(3):284-286.
172. Ottlecz A, Koltai M, Gecse A. Further studies on the antiinfammatory effect of insulin. Agents Actions. 1977;7:487-491.
173. Ottlecz A, Gecse A, Koltai M, West GB. Involvement of the kinin system in the insulin-induced inhibition of carrageenin oedema in rats. Monogr Allerg y. 1977;12:131-137.
174. Boichot E, Sannomiya P, Escofier N, et al. Endotoxin-induced acute lung injury in rats. Role of insulin. Pulm Pharmacol Ther. 1999;12(5):285-290.
175. Das UN. Is insulin an antiinflammatory molecule? Nutrition. 2001;17(5):409-413.
176. Kuboki K, Jiang Z Y, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specifc vascular action of insulin. Circulation. 2000;101(6):676-681.
177. Kojda G, Harrison D. Interaction between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999;43(3): 562-571.
178. Sakaue S, Nishihira J, Hirokawa J, et al. Regulation of macrophage migration inhibitory factor (MIF) expression by glucose and insulin in adipocytes in vitro. Mol Med. 1999;5(6):361-371.
179. Waeber G, Calandra T, Roduit R, et al. Insulin secretion is regulated by the glucose-dependent production of islet beta cell mac-rophage migration inhibitory factor. Proc Natl Acad Sci U S A. 1997;94(9):4782-4787.
180. Hirokawa J, Sakaue S, Furuya Y, et al. Tumor necrosis factor alpha regulates the gene expression of macrophage migration inhibitory factor through tyrosine kinase-dependent pathway in 3T3-L1 adipocytes. J Biochem (Tokyo). 1998;123(4):733-739.
181. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245(6):621-625.
182. Das UN. Possible benefcial action(s) of glucose-insulin-potassium regimen in acute myocardial infarction and infammatory conditions: a hypothesis. Diabetologia. 2000;43(8):1081-1082.
183. Das UN. Can glucose-insulin-potassium regimen suppress infamma-tory bowel disease? Med Hypotheses. 2001;57(2):183-185.
184. Das UN. Hypothesis: can glucose-insulin-potassium regimen in combination with polyunsaturated fatty acids suppress lupus and other infammatory diseases? Prostaglandins Leukot Essent Fatty Acids. 2001;65(2):109-113.
185. Li J, Zhang H, Wu F, et al. Insulin inhibits tumor necrosis factor-α-induction in myocardial ischemia/reperfusion: role of Akt and endothelial nitric oxide synthase phosphorylation. Crit Care Med. 2008;36(5):1551-1558.
186. Reade MC, Fink M P. Bench-to-bedside review: amelioration of acute renal impairment using ethyl pyruvate. Crit Care. 2005;9(6):556-560.
187. Sims CA, Wattanasirichaigoon S, Menconi MJ, Ajami AM, Fink M P. Ringer's ethyl pyruvate solution ameliorates ischemia/ reperfusion-induced intestinal mucosal injury in rats. Crit Care Med. 2001;29(8):1513-1518.
188. Tawadrous ZS, Delude RL, Fink M P. Resuscitation from hemorrhagic shock with Ringer's ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock. 2002;17(6):473-477.
189. Dobsak P, Courderot-Masuyer C, Zeller M, et al. Antioxidative properties of pyruvate and protection of the ischemic rat heart during cardioplegia. J Cardiovasc Pharmacol. 1999;34(5):651-659.
190. Cicalese L, Lee K, Schraut W, Watkins S, Borle A, Stanko R. Pyruvate prevents ischemia-reperfusion mucosal injury of rat small intestine. Am J Surg. 1996;171(1):97-100.
191. Venkataraman R, Kellum JA, Song M, Fink M P. Resuscitation with Ringer's ethyl pyruvate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate concentrations in a rat model of lipopolysaccharide-induced shock. Shock. 2002;18(6):507-512.
192. Das UN. Pyruvate is an endogenous anti-infammatory and anti-oxidant molecule. Med Sci Monit. 2006;12(5):RA79-RA84.
193. Das UN. Is pyruvate an endogenous anti-infammatory molecule? Nutrition. 2006;22(9):965-972.
194. Das UN. Ethyl pyruvate in sepsis. Adv Sepsis. 2007;6:10-15.
195. Belayev L, Marcheselli VL, Khoutorova L, et al. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotec-tion. Stroke. 2005;36(1):118-123.
196. Das UN. Albumin infusion therapy in stroke, sepsis and the critically ill. Curr Nutr Food Sci. 2008;4:217-226.
197. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic infammatory response to endotoxin. Nature. 2000;405(6785):458-462.
198. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of infammation. Nature. 2003;421(6921):384-388.
199. Karimi K, Bienenstock J, Wang L, Forsythe P. The vagus nerve modulates CD4+ T cell activity. Brain Behav Immun. 2010;24(2):316-323.
200. Westman M, Engström M, Catrina AI, Lampa J. Cell specific synovial expression of nicotinic alpha 7 acetylcholine receptor in rheumatoid arthritis and psoriatic arthritis. Scand J Immunol. 2009;70(2):136-140.
201. Bruchfeld A, Goldstein RS, Chavan S, et al. Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis. J Intern Med. 2010;268(1):94-101.
202. van Maanen MA, Stoof S P, Larosa GJ, Vervoordeldonk MJ, Tak P P. Role of the cholinergic nervous system in rheumatoid arthritis: aggravation of arthritis in nicotinic acetylcholine receptor alpha7 subunit gene knockout mice. Ann Rheum Dis. 2010;69(9): 1717-1723.
203. Jobst BC. Electrical stimulation in epilepsy: vagus nerve and brain stimulation. Curr Treat Options Neurol. 2010;12(5): 443-453.
204. Li WG, Gavrila D, Liu X, et al. Ghrelin inhibits proinfammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation. 2004;109(18):2221-2226.
205. Wu R, Dong W, Cui X, et al. Ghrelin down-regulates proinfammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg. 2007;245(3):480-486.
206. Wu R, Zhou M, Das P, et al. Ghrelin inhibits sympathetic nervous activity in sepsis. Am J Physiol Endocrinol Metab. 2007; 293(6):E1697-E1702.
207. Chorny A, Anderson P, Gonzalez-Rey E, Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol. 2008;180(12): 8369-8377.
208. Wu R, Dong W, Zhou M, et al. Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am J Respir Crit Care Med. 2007;176(8):805-813.
209. Chang L, Zhao J, Yang J, Zhang Z, Du J, Tang C. Therapeutic effects of ghrelin on endotoxic shock in rats. Eur J Pharmacol. 2003;473(2-3):171-176.